ArcticZymes Technologies (AZT)

BioMed · november 4, 2018, 11:02pm

https://www.wounds-uk.com/download/resource/7620

TyrionIV · november 5, 2018, 1:01am

Tror det må være en feil i table 2 under woulgan etter 52 uker… 3378 pund tror jeg skal være det korrekte… eller er det noe jg misforstår med den tabellen?

TekBot · november 13, 2018, 1:47pm

Biotec Pharmacon will present at Biotech & Money, Investival Showcase

Biotec Pharmacon ASA (OSE:BIOTEC) will present at the Biotech & Money,
Investival Showcase Conference taking place in London today, Tuesday 13.
November. Estimated start of the presentation will be at 14.45 CET. Speaker will
be CEO Christian Jørgensen.
Please find the presentation attached.
For further information
Børge Sørvoll
CFO
+47 952 90187
borge.sorvoll@biot

Ekstern link: https://newsweb.oslobors.no/message/463471

Nyheten er levert av OBI.

http://www.netfonds.no/quotes/release.php?id=20181113.OBI.20181113S81

TekBot · november 13, 2018, 8:29pm

Biotec renews clinical trial agreement with Memorial Sloan Kettering Cancer Center

(Tromsø 13 November 2018) Biotec Pharmacon’s (OSE:BIOTEC) subsidiary Biotec BetaGlucans has renewed the clinical trial agreement (CTA) with Memorial Sloan Kettering Cancer Center (MSK) to cover the full study period for the ongoing clinical trial called «Phase I/II Trial of a Bivalent Vaccine with the Immunological Adjuvant OPT-821, in Combination with Oral ß-glucan for High-Risk Neuroblastoma".

The clinical trial combines the use of a Memorial Sloan Kettering developed therapeutic vaccine against high-risk neuroblastoma in children with the use of Biotec BetaGlucans’ immunomodulatory product Soluble Beta-Glucan (SBG®). The CTA regulates the obligation of supply of study drug from Biotec to finalise the study, the obligation for MSK to provide Biotec with study data as well as how intellectual property rights arising from the study shall be handled between the parties.

The study has per end of October 2018 accrued 200 patients and has now been expanded to treat up to 260 patients having high-risk neuroblastoma. In the expanded and now randomised study, patients will either continue to be given SBG from week 6 after the 3rd vaccination, or from start of the vaccine treatment in order to investigate if SBG could induce an earlier adjuvant effect to the GD2 cancer antigen. The additional 60 patients are expected to be recruited to the study protocol by end of 2019.

“Neuroblastoma is a devastating disease and we are proud to be associated with research into finding treatment options for it. We are equally excited to extend our long-lasting relationship with Memorial Sloan Kettering Cancer Center, and look forward to follow the progress of the study”, says CEO Christian Jørgensen

For more information, please contact

CEO
Christian Jørgensen
Mob +47 47 79 24 57
[email protected]

About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics.

Ekstern link: http://publish.ne.cision.com//Release/ViewReleaseHtml/CBD67BD8DC39C496E0C856B0705FC7D6
Ekstern link: http://mb.cision.com/Main/1090/2671351/944230.pdf

Nyheten er levert av Cision.

http://www.netfonds.no/quotes/release.php?id=20181113.Cision.20181113:BIT:8351:0

BioMed · november 13, 2018, 8:31pm

TekBot · november 14, 2018, 10:16am

14/11-2018 11:15:58: (BIOTEC) Biotec Pharmacon - Mandatory notification of trade

Vis børsmeldingen

http://www.netfonds.no/quotes/release.php?id=20181114.OBI.20181114S54

Savepig · november 19, 2018, 6:07pm

Sprekt!

TekBot · desember 13, 2018, 2:58pm

13/12-2018 15:56:35: (BIOTEC) ArcticZymes signs new supply agreement for enzyme, Cod UNG

ArcticZymes AS, a leader in the development and commercialization of enzymes applied to molecular diagnostics, gene therapy, and protein purification, announces a new dual track supply agreement for its specialized enzyme, Cod UNG.

ArticZymes’ Japanese customer intends to develop and manufacture molecular biology assay products containing Cod UNG for the research market and molecular diagnostic kits. In addition, the company has agreed to channel ArticZymes’ enzyme as a stand-alone product to its own existing customers, with specific focus on the Chinese market where it has identified a need.
…

Vis børsmeldingen

Biotec Pharmacon anticipates the deal to be worth approximately 1 million NOK of revenue in 2019 with a potential recurring revenue stream of 1-3 million NOK each subsequent year.

ArcticZymes Managing Director Jethro Holter said:

“The quality of our customer and the dual structure of the deal is great validation of our Cod UNG enzyme. By having two different channels through which to sell it - via molecular biology assay kits and via direct sales - this is an ideal position to be in.”

Christian Jørgensen, CEO, added:

“Today’s deal is a good demonstration of how our new commercialisation team is operating, as reported in the Q3 results. This is a competitive market to operate in, which is why we are proud of our portfolio of top quality, specialized enzyme products which are in demand from our customers and their customers. We look forward to further growing our pipeline of products and deals in the near year.”

For more information, please contact:

Biotec Pharmacon
CEO Christian JørgensenMD Tel: +47 47 79 24 57
ArcticZymes, Jethro Holter Tel: +47 46 85 91 45
[email protected]

Instinctif Partners
Melanie Toyne-Sewell / Tel: +44 207 457 2020
Christelle Kerouedan [email protected]
/Deborah Bell

About Biotec Pharmacon ASA

Biotec Pharmacon ASA is a biotechnology company developing, producing and marketing novel recombinant enzymes and immune modulating beta-glucans. It is the parent company of ArcticZymes AS and Biotec BetaGlucans AS.
For more information, please visit the website: www.biotec.no.

About ArticZymes

ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.
For more information, please visit: www.arcticzymes.com.

http://www.netfonds.no/quotes/release.php?id=20181213.Cision.20181213:BIT:7044:0

Otard · desember 14, 2018, 6:40am

Du verden. En børsmelding om inntekter som dekker kostnadene for 1 ansatt sånn cirka

TekBot · desember 20, 2018, 2:56pm

20/12-2018 15:55:30: (BIOTEC) ArcticZymes and Vectron Biosolutions sign license agreement on recombinant enzyme expression technology

(Tromsø 20. December 2018) Biotec Pharmacon’s (OSE: Biotec) subsidiary
ArcticZymes and Vectron Biosolutions AS (Vectron) have signed a non-exclusive
license agreement for recombinant manufacturing of enzymes.
…

Vis børsmeldingen

ArcticZymes is a leader in the development and commercialization of novel
enzymes applied to molecular biology kits, In Vitro Diagnostics (IVD), gene
therapy, and protein purification. Vectron supplies the life science industry
with superior broad-host-range vector technology and solutions for industrial
level production of recombinant proteins.

High yield recombinant expression of proteins and enzymes in host-microorganisms
is a key challenge for the manufacturing of enzyme products and the diverse
nature of enzymes makes it difficult to apply a generic method. The two
companies have collaborated in two projects, financed by Innovation Norway and
the Research Council of Norway, in order to test the feasibility and
optimization of Vectron’s technology for the production of ArcticZymes enzymes.
The results from the projects have shown a high success rate on a large set of
target enzymes in ArcticZymes’ discovery pipeline and a high yield in scaled-up
production processes. This agreement allows for more efficient discovery of new
enzymes and improved yield in manufacturing of ArcticZymes’ products.

ArcticZymes will pay royalties depending on sales of products manufactured using
Vectrons’ technology.

Olav Lanes, Director of R&D and Applications at ArcticZymes AS, added:

“Through our existing partnership we have successfully proven that Vectron’s
technology is efficient for use in recombinant manufacturing of ArcticZymes’
enzyme products. This agreement expands ArcticZymes’ toolbox for more efficient
enzyme discovery and improved enzyme yield and is important to speed growth of
our product offering”.

Trond Erik Aune, CEO of Vectron Biosolutions, said:

“We are encouraged to see that our technology works on the unique enzyme targets
at ArcticZymes, as these targets are often hard to express and produce
successfully. This is a valuable expansion of the use of our technology in the
life science market.”

For more information, please contact:

Biotec Pharmacon
CEO Christian Jørgensen Tel: +47 47 79 24 57
MD ArcticZymes, Jethro Tel: +47 46 85 91 46
Holter Email: [email protected]

Instinctif Partners
Melanie Toyne-Sewell / Tel: +44 207 457 2020
Christelle Kerouedan [email protected]
/Deborah Bell

About Biotec Pharmacon ASA

Biotec Pharmacon ASA is a biotechnology company developing, producing and
marketing novel recombinant enzymes and immune modulating beta-glucans. It is
the parent company of ArcticZymes AS and Biotec BetaGlucans AS.

For more information, please visit the website: www.biotec.no.

About ArcticZymes

ArcticZymes develops, produces and markets enzymes of marine origin used in
molecular DNA technologies and diagnostics, representing growth markets where
rapid technological developments are creating a strong demand for new and
improved enzymes.

For more information, please visit: www.arcticzymes.com.

About Vectron Biosolutions AS

Vectron Biosolutions AS supplies the life science industries with superior
technologies and solutions for robust and cost-efficient production of
recombinant proteins in E. coli and other bacteria.

For more information, please visit: www.vectronbiosolutions.co

http://www.netfonds.no/quotes/release.php?id=20181220.OBI.20181220S170

Savepig · januar 7, 2019, 11:13pm

BIOTEC gjør et nytt forsøk på å tegne en bunn, ganske lik formasjon som den hadde i midten av oktober.

alt for tynt volum enda men spennende.

BioMed · januar 10, 2019, 5:49pm

BioMed · januar 10, 2019, 5:50pm

https://blogg.uit.no/helsefak/kan-bandasje-basert-pa-nanofiber-hjelpe-pasienter-med-kroniske-sar/?fbclid=IwAR3SDCZn8IuHuj4AFigtAPLX_FECudbxWdsnHueSN6hMMgMN-eb7FuP22f4

BioMed · januar 18, 2019, 11:18am

Bra start i dag også! RT: 4,75 +8%

TekBot · januar 23, 2019, 2:46pm

23/01-2019 15:45:39: (BIOTEC) Biotec Pharmacon ASA: Invitation to presentation of Q4 2018 results

Biotec Pharmacon presents its report for the fourth quarter 2018 on
Wednesday, 30.January 2019. The presentation will be given by CEO Christian
Jørgensen and CFO Børge Sørvoll.
…

Vis børsmeldingen

The presentation starts at 08:30 a.m. and will be in English.

Venue: Hotel Continental, Stortingsgata 24/26, Oslo.

The presentation can also be followed as a live webcast from Hegnar TV on
www.biotec.no or http://webtv.hegnar.no/presentation.php?webcastId=97601947. It
will be possible to post questions through the webcast console.

The report for the fourth quarter 2018 will be available on www.newsweb.no and
on the company’s homepage, www.biotec.no from 07:00 a.m. on 30. January 2019.

For further information, please contact:
CFO
Børge Sørvoll
+47 952 90187
borge.sorvoll

http://www.netfonds.no/quotes/release.php?id=20190123.OBI.20190123S44

TekBot · januar 29, 2019, 7:04am

29/01-2019 08:03:00: (BIOTEC) Biotec Pharmacon finalises Post Market study on Woulgan®

Biotec BetaGlucans filed an application to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in June 2018 to finalise the study. The application was accepted in November 2018 and all patients have now been treated.

The study, initiated in 2015, was part of the MHRA’s requirements to assess the safety and usefulness of Woulgan® before approval as a medical device in the management of wounds. The study aimed to recruit 60 patients for treatment with Woulgan® gel and 20 with a commercial hydrogel from Smith & Nephew (Intrasite®). The study was allowed to be finalised after having recruited just above 60 patients in total.
…

Vis børsmeldingen

In parallel with this study, Biotec Pharmacon ran a large 300-patient clinical study in the UK (including diabetic patients), demonstrating the Woulgan® gel’s excellent safety profile and its clinical efficacy and usability. This evidence, alongside case studies, has contributed to the MHRA’s favourable decision to allow the completion of the PMCF study.

The Contract Research Organisation handling the study is now collecting and evaluating the data from the four clinical investigation sites. The results are expected in late Q2 2019.

Christian Jørgensen, CEO, said:

“The acceptance from the MHRA and study completion is a positive step forwards for the Company. These results expected mid-year will provide further validation of our Woulgan® gel product in wound care management.”

-ENDS-

For more information, please contact:

Biotec Pharmacon
CEO Christian Jørgensen Tel: +47 47 79 24 57
Email: [email protected]
Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan / Deborah [email protected]
Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high tech products in several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About Biotec BetaGlucans

BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan (BG) products derived from the cell wall of the Saccharomyces cerevisiae.

The active pharmaceutical ingredients display immunomodulatory properties addressing high unmet healthcare needs, such as chronic wound healing or cancer.

Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the wound healing product (Woulgan®) and is also being tested in a R&D programme as an adjuvant for immunotherapeutic cancer treatments.

For more information, please visit: https://biotec.no/about-us/biotec-betaglucans/.

http://www.netfonds.no/quotes/release.php?id=20190129.Cision.20190128:BIT:4961:0

TekBot · januar 29, 2019, 7:04am

29/01-2019 08:03:15: (BIOTEC) Biotec Pharmacon finalises Post Market study on Woulgan

Tromsø, Norway, 29 January 2019 - Biotec Pharmacon’s (OSE: Biotec) has announced
that its subsidiary, Biotec BetaGlucans, has finalised treatment in a UK Post
Market Clinical Follow-up (PMCF) study on its wound care gel, Woulgan®, in
…

Vis børsmeldingen

diabetic foot ulcer patients.
Biotec BetaGlucans filed an application to the UK Medicines and Healthcare
Products Regulatory Agency (MHRA) in June 2018 to finalise the study. The
application was accepted in November 2018 and all patients have now been
treated.

The study, initiated in 2015, was part of the MHRA’s requirements to assess the
safety and usefulness of Woulgan® before approval as a medical device in the
management of wounds. The study aimed to recruit 60 patients for treatment with
Woulgan® gel and 20 with a commercial hydrogel from Smith & Nephew (Intrasite®).
The study was allowed to be finalised after having recruited just above 60
patients in total.

In parallel with this study, Biotec Pharmacon ran a large 300-patient clinical
study in the UK (including diabetic patients), demonstrating the Woulgan® gel’s
excellent safety profile and its clinical efficacy and usability. This evidence,
alongside case studies, has contributed to the MHRA’s favourable decision to
allow the completion of the PMCF study.

The Contract Research Organisation handling the study is now collecting and
evaluating the data from the four clinical investigation sites. The results are
expected in late Q2 2019.

Christian Jørgensen, CEO, said:

“The acceptance from the MHRA and study completion is a positive step forwards
for the Company. These results expected mid-year will provide further validation
of our Woulgan® gel product in wound care management.”

-ENDS-

For more information, please contact:

Biotec Pharmacon
CEO Christian Jørgensen Tel: +47 47 79 24 57
Email: [email protected]
Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan / Deborah [email protected]
Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsoe to offer niche and high tech products in
several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans
addressing high unmet healthcare needs, such as chronic wound healing and as an
adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec
Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About Biotec BetaGlucans

BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan
(BG) products derived from the cell wall of the Saccharomyces cerevisiae.

The active pharmaceutical ingredients display immunomodulatory properties
addressing high unmet healthcare needs, such as chronic wound healing or cancer.

Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the
wound healing product (Woulgan®) and is also being tested in a R&D programme as
an adjuvant for immunotherapeutic cancer treatments.

For more information, please visit: https://biotec.no/about-us/biotec
-beta

http://www.netfonds.no/quotes/release.php?id=20190129.OBI.20190129S7

TekBot · januar 30, 2019, 6:01am

30/01-2019 07:00:07: (BIOTEC) Biotec Pharmacon Q4 2018 Results

Tromsø, Norway, 30 January 2019 - Biotec Pharmacon (OSE: Biotec) announces its
Q4 2018 results and full year 2018 results to 31 December 2018.
Highlights for Q4 and full year 2018
…

Vis børsmeldingen

· Group sales were up 10% to NOK 19.5 million in Q4 2018 (Q4 2017: NOK 17.7
million), due to record enzymes sales and animal health sales. Annual sales were
NOK 66.8 million (2017: NOK 66.7 million).
· ArcticZymes had record high fourth quarter sales of NOK 10.6 million (Q4
2017: NOK 8.8 million).
· Woulgan® continues to generate recurring revenues with NOK 0.9 million for
the quarter (Q4 2017: NOK 0.6 million), driven primarily by the German market.
Annual sales up 26% to NOK 2.9 million (2017: NOK 2.3 million).
· EBITDA of NOK -1.6 million in Q4 (Q4 2017: NOK -7.2 million) as a result of
stronger sales and cost control. EBITDA for the full year significantly improved
to NOK -11.9 million (2017: NOK -22.9 million).
· Operating expenses for Q4 decreased to NOK 18.5 million (Q4 2017: NOK 19.9
million) and annually NOK 65.3 million (2017: NOK 73.8 million).
· Cash balance as at 31 December 2018: NOK 31.7 million (FY 2017: NOK: 30.6
million).
· ArcticZymes signed a new supply agreement for Cod UNG (13 December 2018) and
a license agreement with Vectron Biosolutions (20 December 2018).
· New VP Wound Care appointed with aim of strengthening sales growth in the
UK, Nordics and other European countries for 2019.

CEO Christian Jørgensen comments:

"In Q4, we saw record sales of enzymes from the ArcticZymes division due to
strong customer sales and launches of new products. In the BetaGlucans division,
we experienced solid animal health sales and saw encouraging growth in Woulgan
sales, driven by the German market.

"Stronger sales and careful cost control reduced the overall deficit in EBITDA
by over 50%, giving us the best result so far as a company since 2005.

"Strategically, the priority for the business is twofold. ArcticZymes will
continue launching new products as demanded by customers, and we aim to grow it
both organically as well as looking for inorganic growth opportunities. The goal
for Biotec BetaGlucans will be to further build the Woulgan franchise, focussing
on the growing German market and strengthening sales in the UK, Nordics and
other European markets.

“We believe we are stronger as a business going into 2019 than in earlier years.
We aim to continue driving business development efforts whilst managing the
Company’s resources carefully into 2019.”

-Ends-

Fourth Quarter 2018 Results Presentation and Webcast

A presentation by Biotec Pharmacon’s CEO, Christian Jørgensen, and CFO, Børge
Sørvoll, will take place today, 30 January 2019, at 08:30 am CET at Hotel
Continental, Stortingsgata 24/26, Oslo.

The presentation can also be followed as a live webcast from Hegnar TV on
www.biotec.no (https://protect-eu.mimecast.com/s/JfV3C1wDYUZ3XYhph
-Hn?domain=biotec.no) or
[http://webtv.hegnar.no/presentation.php?webcastId=97601947 (https://protect](http://webtv.hegnar.no/presentation.php?webcastId=97601947 (https://protect)
-eu.mimecast.com/s/hmSYC2kEgim1Qwt2wz49?domain=webtv.hegnar.no). It will be
possible to post questions through the webcast console.

The results, report and presentation for the fourth quarter 2018 will be
available on www.newsweb.no (https://protect
-eu.mimecast.com/s/ax_EC4xJkS8gx1SMlEBY?domain=newsweb.no) and on the Company’s
homepage, www.biotec.no (https://protect-eu.mimecast.com/s/JfV3C1wDYUZ3XYhph
-Hn?domain=biotec.no) from 07:00 am on 30 January 2019.

Ends -

For more information, please contact:

Biotec Pharmacon
CEO Christian JørgensenCFO Tel: +47 47 79 24 57
Børge Sørvoll Tel: +47 95 29 01 87
[email protected]

Instinctif Partners
Melanie Toyne-Sewell / Tel: +44 207 457 2020
Christelle Kerouedan [email protected]
/Deborah Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsø to offer niche and high tech products in several
biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans
addressing high unmet healthcare needs, such as chronic wound healing and as an
adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec
Pharmacon is headquartered in Tromsø, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

http://www.netfonds.no/quotes/release.php?id=20190130.OBI.20190130S9

TekBot · januar 30, 2019, 6:01am

30/01-2019 07:00:09: (BIOTEC) Biotec Pharmacon Q4 2018 Presentation

FiloD · januar 30, 2019, 8:44am

Et sterkt regnskap fra BP. Stor cost kontroll og fremgang for AZ.

Det går langsomt, men det går fremover. Woulgan er og bliver dog skuffende.
Det ser ut til å løsne for AZ og de blir helt sikkerde dem som skal bringe BP på fote igjen.

Aktien er riktig priset nu, men kan bli interessant igen når AZ blir mere stabil i omsetningen.